Safety and Efficacy of the TransDiscal System Versus Medical Management in Treating Chronic Discogenic Low Back Pain (COLD)
2018년 6월 12일 업데이트: Halyard Health
A Prospective, Randomized, Multi-Center, Open-Label Clinical Trial Comparing Disc Biacuplasty With Medical Management for Discogenic Lumbar Back Pain
The primary objective of this randomized controlled trial is to evaluate the safety and efficacy of the TransDiscal System (TDS) in treating discogenic pain of the lumbar spine using a modified disc biacuplasty procedure.
The primary efficacy measure will be the Visual Analog Scale (VAS) at 6 months post treatment/randomization and the TransDiscal System will be compared against medical management (standard of care).
연구 개요
상세 설명
The intervertebral discs serve as joints between the vertebral bodies, providing both structural support and flexibility to the spinal column. Intervertebral discs do not remain structurally intact over a lifetime and degenerate as a natural part of aging. Degenerated discs do not react to stresses and forces the same as healthy discs. When too much stress is applied to a degenerated disc, tears can result. Evidence suggests that when a tear is present, sensory nerve endings can grow into the tear and transmit pain.
The TransDiscal System (TDS) is a medical device that is used in a procedure called Disc Biacuplasty and is currently available in the United States and throughout the world. The TDS enables the back of the disc to be heated to high enough temperatures to ablate the nerves inside that are transmitting pain, while maintaining low enough temperatures to prevent damage to surrounding tissues. The TDS uses two electrodes, located at the ends of two thin probes, which are placed on both sides of the back of the intervertebral disc by inserting them through the skin into the disc using x-ray guidance. Radiofrequency (RF) current flows in the disc between the two electrodes, heating the tissue in the disc to the desired temperature. The study evaluates a modified heating protocol than what is currently in clinical use which should allow for a larger area of the back of the disc to be heated.
연구 유형
중재적
등록 (실제)
67
단계
- 해당 없음
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 장소
-
-
District of Columbia
-
Washington, District of Columbia, 미국, 20037
- George Washington University Hospital
-
-
Florida
-
Orlando, Florida, 미국, 32806
- Compass Research
-
-
Illinois
-
Bloomington, Illinois, 미국, 61701
- Millennium Pain Center
-
-
Maryland
-
Silver Spring, Maryland, 미국, 20910
- Metro Orthopedics & Sports Therapy
-
-
New Jersey
-
Linwood, New Jersey, 미국, 08221
- PainCare
-
-
North Carolina
-
Winston-Salem, North Carolina, 미국, 27103
- Center for Clinical Research
-
-
Ohio
-
Cleveland, Ohio, 미국, 44195
- Cleveland Clinic
-
-
Texas
-
Arlington, Texas, 미국, 76018
- JPS Orthopedic & Sports Medicine
-
-
Washington
-
Seattle, Washington, 미국, 98105
- Center for Pain Relief, University of Washington
-
-
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
21년 이상 (성인, 고령자)
건강한 자원 봉사자를 받아들입니다
아니
연구 대상 성별
모두
설명
Inclusion Criteria:
- Age ≥21 years
- Able to understand the informed consent and able to complete outcome measures
- Objective measurements indicating functional impairment related to low back pain
- Stabilized on pain medication regimen for >2 months as defined by a <10% change in dosage
- History of chronic low back pain (>6 months) unresponsive to non-operative care (including physical therapy, anti-inflammatory medication, epidurals, diagnostic facet joint/medial branch blocks, and sacroiliac joint interventions as performed or deemed appropriate by the Investigator)
- Score ≥5 on the Visual Analog Scale (VAS) relating specifically to the average daily low back pain
- Back pain more prominent than leg pain which is commonly exacerbated by flexion or bending or prolonged sitting.
- Single level concordant pain reproduction present on lumbar discography in desiccated disc. Magnetic resonance Imaging (MRI) image also supports discography findings. Changes in other disc spaces in the lumbar region do not demonstrate neural compressive lesion.
- Disc height at least 50% of adjacent control disc
Exclusion Criteria:
- Evidence of compressive radiculopathy with predominant leg pain
- Evidence of nucleus pulposus herniation or free disc fragments on MRI
- Evidence of > 2 discs dessicated based on MRI or symptomatic involvement of more than one lumbar disc levels.
- Asymptomatic disc bulges > 5 mm at the treatment level.
- Prior lumbar surgery of any kind at the treatment level (micro-discectomies, and/or minimally invasive procedures at other levels that are not excluded)
- Prior spinal fusion below the T10 Level
- Symptoms or signs of lumbar canal stenosis at any level
- Evidence of structural abnormality at the lumbar level (except non-symptomatic spondylolysis resulting in spondylolithesis no more than Grade 1 upon flexion and extension)
- Any generalized pain or multifocal pain,conversion or multiple non-anatomical complaints
- Pending or active compensation claim, litigation or disability income remuneration (secondary gain)
- Chronic pain associated with significant psychosocial dysfunction
- Beck's Depression Index (BDI) score >20
- Current pregnancy, recent delivery (within 3 months of consent) or the intent of becoming pregnant during the study period.
- Systemic or localized infection at the anticipated needle entry site (subject may be considered for inclusion once infection is resolved)
- Discitis
- Allergies to any medication to be used in the procedure
- Present symptomatic lumbar spinal fracture
- History of uncontrolled coagulopathy, ongoing coagulation treatment or unexplained or uncontrollable bleeding that is uncorrectable
- Progressive neurological deficits
- Within the preceding 2 years, subject has suffered from active narcotic addiction, substance abuse or alcohol abuse
- Current prescribed opioid medications equivalent to >120 mg of morphine per 24 hours
- Uncontrolled immunosuppression (e.g. Acquired Immune Deficiency Syndrome [AIDS], cancer, diabetes, etc.)
- Body Mass Index (BMI) >32.5 kg/m^2
- Participating in another clinical trial/investigation 30 days prior to signing informed consent
- Negative or indeterminate lumbar discography results as assessed per International Spine Intervention Society (ISIS) guidelines
- Subject unwilling or unable to comply with follow up schedule or protocol requirements.
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: TransDiscal System
Kimberly-Clark TransDiscal System in addition to standard medical management
|
Surgical Procedure using the TransDiscal System to perform disc biacuplasty.
다른 이름들:
|
|
다른: Medical Management
Standard medical management
|
Standard medical management, physical therapy, and lifestyle changes.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in Average Daily Pain Visual Analog Scale (VAS) Score Between Screening and Follow up.
기간: Baseline and 6 months
|
Visual Analog Scale (NRS) - score range = 0 - 10. "0" corresponds to "no pain" and "10" indicates "worst pain imaginable".
The means of these scores and their respective standard deviations are reported for each study group.
|
Baseline and 6 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percentage of Study Group Subjects With Greater Than 2 Points Decrease or 30% Drop in Average Daily Pain Related Visual Analog Scale (VAS) Score.
기간: Baseline and 6 months
|
Visual Analog Scale (NRS) - score range = 0 - 10. "0" corresponds to "no pain" and "10" indicates "worst pain imaginable".
The means of these scores and their respective standard deviations are reported for each study group.
|
Baseline and 6 months
|
|
Mean Change in Score of Short Form 36-Physical Functioning (SF36-PF) From Screening to 6 Month Follow up Visit
기간: Baseline and 6 months
|
Short Form 36-PF - score range = 0 - 100.
"0" corresponds to "greatest disability" and "100" indicates "no disability".
The means of these scores and their respective standard deviations are reported for each study group.
|
Baseline and 6 months
|
|
Mean Change in Score of EuroQuol 5d Visual Analog Scale (EQ-5d VAS) Between Screening and 6 Month Follow up Visit
기간: Baseline and 6 months
|
EQ-5d VAS - score range = 0 - 100.
"0" corresponds to the "worst imaginable health state" and "100" indicates the "best imaginable health state".
The means of these scores and their respective standard deviations are reported for each study group.
|
Baseline and 6 months
|
|
Mean Change in Score of Beck's Depression Inventory (BDI) Between Screening and 6 Month Follow up Visit
기간: Baseline and 6 months
|
BDI - score range = 0 - 63. "0" corresponds to "minimal depression" and "63" indicates "severe depression".
The means of these scores and their respective standard deviations are reported for each study group.
|
Baseline and 6 months
|
|
Mean Change in Score of Patient Global Impression of Change (PGIC) Between Screening and 6 Month Follow up Visit
기간: Baseline and 6 months
|
PGIC - score range = 1 - 7. "1" corresponds to "very much improved" and "7" indicates "very much worse" pertaining to overall activity, symptoms, emotions, and quality of life.
The means of these scores and their respective standard deviations are reported for each study group.
|
Baseline and 6 months
|
|
Mean Change in Score of Oswestry Disability Index (ODI) Between Screening and 6 Month Follow up Visit
기간: Baseline and 6 Months
|
ODI - score range = 0 - 100.
"0" corresponds to "no disability" and "100" indicates the "maximum disability possible".
The means of these scores and their respective standard deviations are reported for each study group.
|
Baseline and 6 Months
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
스폰서
수사관
- 연구 책임자: David Curd, MS, Halyard Health, Inc.
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작
2010년 12월 1일
기본 완료 (실제)
2014년 12월 1일
연구 완료 (실제)
2015년 4월 1일
연구 등록 날짜
최초 제출
2010년 11월 29일
QC 기준을 충족하는 최초 제출
2010년 12월 16일
처음 게시됨 (추정)
2010년 12월 20일
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
2018년 7월 10일
QC 기준을 충족하는 마지막 업데이트 제출
2018년 6월 12일
마지막으로 확인됨
2015년 3월 1일
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .